INTRODUCTION
Regenerative medicine has been an emerging field that represents replacement of lost or damaged tissues in the human body through either cellular transplantation or endogenous repair. It has been considered that stem cells are the potential mediators that function as reservoir for repair and regeneration of damaged tissues, because of its ability of differentiation into many different lineages of specialized cells [1] [2] [3] . Recently, the discovery of induced pluripotent stem cells (iPSC) which have differentiation capacity into all kind of cells in the body, called pluripotency, encourages the synthesis of scientific principles and technology in applications in regenerative medicine.
iPS cells can be achieved by reprogramming somatic cells using reprogramming factors and can undergo self-renewal as well as differentiate into all three germ layers [4, 5] . The in vitro generation of pluripotent cells without the use of embryonic material has been rendered a more suitable source for regenerative medicine compared with nuclear transfer-embryonic stem cells (NT-ESC) [6, 7] or somatic cell nuclear transfer (SCNT) [8, 9] . Moreover, the one of advantages of iPSC is to overcome immune rejection that occurs when one uses cells of an individual to generate pluripotent stem cells. These features make iPSC a useful tool for drug screening, the human disease model and cell therapy including autologous transplantation [3, 10, 11] . Thereby, since the initial report of mouse and human iPSCs by Takahashi and Yamanaka group, other groups recapitulated and found the iPSC technology to be more reproducible, effective, safe and a therapeutically compatible iPSC generation for the clinical setting. More studies about recent trends will be further discussed. Induced pluripotent stem cells (iPSC) are specially manipulated cells from somatic cells by the introduction of four factors that are reprogrammed. The properties of iPSC are similar to embryonic stem cells (ESC) characteristic of self-renewal and pluripotency. The technology of reprogramming somatic cells to iPSC enables the generation of patient-specific cells that can be used as powerful tools for drug screening, in vitro models for human disease and autologous transplantation. The iPSC technology provides a priceless resource for regenerative medicine but there are still changing obstacles over the safety of iPSC in avoiding induction of tumorigenicity and maintaining high purity of re-differentiated cells from iPSC to produce more functional cells for cell therapy. A variety of methods to overcome the limitation of iPSC application applied in the clinical setting have been developed. In this review, we summarize the recent progress in iPSC generation and differentiation techniques to facilitate clinical application of iPSC with future potential in regenerative medicine.
ate differentiation of the cells and the risk of tumor formation following cellular transplantation, although the latter concerns regarding tumor development have been overcome by selective drugs to induce cell death of remaining iPSC after differentiation [12, 13] .
There are still many unresolved issues mainly associated with the maturation of cells to a fully functional state. To overcome these limitations, recent research focuses on using devices and materials to help make iPSC into miniature organs to produce more functional cells [14, 15] . This may allow production of more appropriate cells for transplantation, meanwhile other goals for higher reproducibility and efficient differentiation protocol currently remain homework. Discussed here are recent advancements in this field related to regenerative medicine, with an emphasis on iPSC generation applicable in the clinical setting and creating more functional iPSC-derivates.
ADVANCEMENTS OF HUMAN INDUCED PLURIPOTENT STEM CELLS GENERATION FOR ITS CLINICAL APPLICATION
The primary component of reprogramming factors consists of klf4, Oct4, Sox2, and c-Myc which were effective throughout several types of mouse and human cells. Another set including Oct4, Sox2, Nanog, and Lin28 were also enough to reprogram human fibroblasts [16] . Traditionally, iPS cells could be induced from mouse or human fibroblasts through transduction of reprogramming factors mediated by virus systems, which might bring about insertional mutagenesis. In addition, upon re-differentiation of iPSC into target cells, reactivation of reprogramming factors integrated in the donor genome have raised concerns regarding the clinical application due to induction of tumorigenicity [17] . Many studies have been developed to overcome this issue by approaching genome footprint free-/non-integrating iPSC for clinically applicable iPSC generation [18, 19] . Table 1 shows the classified reprogramming techniques based on efficiency, value of footprint, and number of donor types to be reprogrammed as previously reported.
Integrating methods with modification for reprogramming
Initial iPSC generation from mouse and human were mediated by retro-and lenti-virus containing four transcription factors. Those systems cause the integration of transgene into donor genome to allow for insertional mutagenesis, thus limiting use of iPSC for clinic.
Moreover, iPSC generated by virus often maintains transgene expression, although silencing of transgene occurs gradually during iPSC induction, and then finally undergoes silencing in the pluripotent state. Importantly, the efficiency of iPSC generation was much lower than 0.01% [5, 20] . After this first discovery, modifications of reprogramming methods were performed to eliminate the integration of transgene. Soldner et al. reported integration of free-human [21, 22] . We also used Cre-loxP mediated reprogramming methods to generate hiP-SC from human fibroblast cells (Fig. 1 ).
Non-integrating methods for reprogramming
To overcome the main obstacle of clinical implication of iPSC, researchers have been established integration-free iPSC using adenovirus [23] , sendai-virus [24] , proteins [25] , mRNA [26] , miRNA [27] and episomal vector [28] expressing reprogramming factors.
However, these methods are still necessary for much work to be widely used for the following reasons: 1) Need for intensive labor, 
CHARACTERIZATIONS OF REPROGRAMMED CELLS TO IDENTIFY HUMAN INDUCED PLURIPOTENT STEM CELLS
After obtaining reprogrammed cells, identification of iPSC colonies is necessary to determine whether selected the colony is fully reprogrammed by investigating hESC-like morphological criteria, expression of hESC markers endogenously (Tra1-81, Nanog, Oct4, Sox2), loss of transgenes, and ability of differentiation potential as teratoma formation in the case of human iPSC.
The first generated iPSC was selected with ESC-specific gene, 
APPLICATION OF INDUCED PLURIPOTENT STEM CELLS: INDUCED PLURIPOTENT STEM CELLS TECHNOLOGY INTO REGENERATIVE MEDICINE
One of the major challenges for cell therapy using stem cells is host immune rejection of the transplanted cells. To facilitate clinical application of stem cells, it is important to develop therapeutically valuable cells that do not induce an immune rejection. Currently, iPS cell lines can be generated from patients with several genetic disorders [35] . Theses patient-specific derived target cells can serve as easily accessible autologous source for cell replacement therapies as well as drug screening and in vitro disease models [10] .
Thereby, iPSC technology providing potentially unlimited autologous cells is especially attractive for regenerative medicine. Despite the advantages of iPSC-derivates, there still remain many obstacles for transplantation including whether iPSC-derivates are mature functional cells that can be used clinically. Recent progress on iPSC technology including detailed differentiation required to fulfill the promises (or dreams) of stem cell-based therapeutics for human disease will be discussed.
Human induced pluripotent stem cells differentiation in vitro for future therapeutic application
For cell therapy in the clinic setting, clinically applicable hiPSC generation is the first step with the ultimate goal being reproducible differentiation and maximum enrichment to specific cell lineages. While multiple protocols have been developed to generate the clinically relevant cell types including cardiomyocytes [37] , hematopoetic progenitors [38] , neurons [39] , hepatocytes [40] Microfluidic bioreactors have shown their potential to establish highly controllable microenvironmental cues. The 3D niche mimics the in vivo microenvironments to contribute both autocrine and paracrine functions in individual hiPSC [42] . Also, stem cell cultured matrigel-coated polystyrene microcarriers also feasibly expand endodermal cells with high numbers/efficiency in 8 days to greater than 80% as determined by co-expression of Sox17 and Foxa2 [43] . ECM coatings by tissue materials enhanced the maturation of both skeletal progenitors and stem cell derived cardiomyocytes by mimicking the in vivo 3D ECM microenvironment [44] .
Therefore, control of the dynamics of intercellular interactions in multidimensional environments represents powerful approaches to achieve functional manure cell types from pluripotent stem cells.
Organogenesis of human induced pluripotent stem cells based on ex vivo system for future therapeutic application
One of the most exciting developments of hiPSC differentiation is shown in the 3D based organogenesis from iPSC which regenerate brain [45, 46] intestinal [47] and liver [48] organs in a dish, called organoid. Among iPSC derived organoids, we introduced detailed organoid of the liver as we worked this field previously [36] . A co- 
